A new strategic industry partner and the company’s existing investors and the management team have also participated in the round.
The finance will be used support the planned 2013 commercial launch of the RhythmView WorkStation and FIRMap Catheter in Europe and the US as well as to further advance the company’s R&D pipeline and clinical development program.
Topera CEO Edward Kerslake said, "We are pleased to partner with this experienced group of investors as we continue our mission to help clinicians obtain information about the sources sustaining complex arrhythmias to significantly improve long-term patient outcomes while reducing costs to providers and the healthcare system."
In conjunction with the financing, NEA partner Justin Klein has joined Topera’s board of directors.
Topera board of directors chairman Art Taylor said, "With NEA’s long track record of building great companies around transformative innovations, we believe this financing will support an exciting next chapter in Topera’s growth."
